ECSP10010164A - Formulaciones de polvo seco que comprenden derivados del ácido ascórbico - Google Patents

Formulaciones de polvo seco que comprenden derivados del ácido ascórbico

Info

Publication number
ECSP10010164A
ECSP10010164A EC2010010164A ECSP10010164A ECSP10010164A EC SP10010164 A ECSP10010164 A EC SP10010164A EC 2010010164 A EC2010010164 A EC 2010010164A EC SP10010164 A ECSP10010164 A EC SP10010164A EC SP10010164 A ECSP10010164 A EC SP10010164A
Authority
EC
Ecuador
Prior art keywords
dry powder
ascorbic acid
powder formulations
include derivatives
derivative
Prior art date
Application number
EC2010010164A
Other languages
English (en)
Inventor
Jan Trofast
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of ECSP10010164A publication Critical patent/ECSP10010164A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Otolaryngology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La invención proporciona formulaciones farmacéuticas de polvo seco que comprenden un derivado del ácido ascórbico que presenta un comportamiento inhalatorio bueno e inhaladores de polvo seco que las contienen.
EC2010010164A 2007-11-07 2010-05-07 Formulaciones de polvo seco que comprenden derivados del ácido ascórbico ECSP10010164A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US98602607P 2007-11-07 2007-11-07
US7344308P 2008-06-18 2008-06-18

Publications (1)

Publication Number Publication Date
ECSP10010164A true ECSP10010164A (es) 2010-06-29

Family

ID=40626004

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2010010164A ECSP10010164A (es) 2007-11-07 2010-05-07 Formulaciones de polvo seco que comprenden derivados del ácido ascórbico

Country Status (17)

Country Link
US (1) US20110105449A1 (es)
EP (1) EP2217278A1 (es)
JP (1) JP2011503058A (es)
KR (1) KR20100095437A (es)
CN (1) CN101909652A (es)
AU (1) AU2008325290B2 (es)
BR (1) BRPI0819259A2 (es)
CA (1) CA2704639A1 (es)
CO (1) CO6270343A2 (es)
CR (1) CR11419A (es)
DO (1) DOP2010000138A (es)
EA (1) EA201000677A1 (es)
EC (1) ECSP10010164A (es)
IL (1) IL205514A0 (es)
MX (1) MX2010005036A (es)
WO (1) WO2009061273A1 (es)
ZA (1) ZA201003223B (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011120779A1 (en) 2010-04-01 2011-10-06 Chiesi Farmaceutici S.P.A. Process for preparing carrier particles for dry powders for inhalation
CN102302488A (zh) * 2011-07-06 2012-01-04 中山大学 一种针对ccl18靶标的化合物在制备抗乳腺癌药物中的应用
US20150165038A1 (en) * 2012-02-10 2015-06-18 Arven llac Sanayi Ve Ticaret A.S. Compositions comprising muscarinic receptor antagonist and sorbitol
EP2641900A1 (en) 2012-03-20 2013-09-25 Almirall, S.A. Novel polymorphic Crystal forms of 5-(2-{[6-(2,2-difluoro-2-phenylethoxy) hexyl]amino}-1-(R)-hydroxyethyl)-8-hydroxyquinolin-2(1h)-one, heminapadisylate as agonist of the ß2 adrenergic receptor.
JP5087182B1 (ja) 2012-06-13 2012-11-28 クリニプロ株式会社 吸入用パウダーの製造方法
US10111957B2 (en) 2012-07-05 2018-10-30 Arven Ilac Snayi ve Ticaret A.S. Inhalation compositions comprising glucose anhydrous
US10105316B2 (en) 2012-07-05 2018-10-23 Arven llac Sanayi Ve Ticaret A.S. Inhalation compositions comprising muscarinic receptor antagonist
HRP20260435T1 (hr) 2014-09-09 2026-05-08 Vectura Limited Formulacija koja sadrži glikopirolat, postupak i uređaj
AU2016241369A1 (en) * 2015-04-01 2017-11-02 Lupin Atlantis Holdings Sa Process for manufacturing dry powder blends

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6071963A (en) * 1996-11-06 2000-06-06 Roche Vitamins Inc. Water dispersible compositions
GB2326334A (en) * 1997-06-13 1998-12-23 Chiesi Farma Spa Pharmaceutical aerosol compositions
US6315985B1 (en) * 1999-06-18 2001-11-13 3M Innovative Properties Company C-17/21 OH 20-ketosteroid solution aerosol products with enhanced chemical stability
EP1326642A2 (en) * 2000-09-29 2003-07-16 Board of Trustees operating Michigan State University Catecholamine pharmaceutical compositions and methods
US20020085978A1 (en) * 2000-11-10 2002-07-04 Mina Buenafe Degradation-resistant glucocorticosteroid formulations
US20020165207A1 (en) * 2001-05-02 2002-11-07 Richard Rosenbloom Compositions and methods for the treatment of diabetic neuropathy
BRPI0510119A (pt) * 2004-04-23 2007-09-25 Cydex Inc formulação para dpi contendo sulfoaquil éter de ciclodextrina
EP2311793A1 (en) * 2004-12-17 2011-04-20 Cipla Ltd. Crystalline levosalbutamol sulphate (Form II)

Also Published As

Publication number Publication date
AU2008325290B2 (en) 2011-12-08
KR20100095437A (ko) 2010-08-30
CN101909652A (zh) 2010-12-08
JP2011503058A (ja) 2011-01-27
EP2217278A1 (en) 2010-08-18
EA201000677A1 (ru) 2010-12-30
BRPI0819259A2 (pt) 2019-10-01
US20110105449A1 (en) 2011-05-05
IL205514A0 (en) 2010-12-30
AU2008325290A1 (en) 2009-05-14
CA2704639A1 (en) 2009-05-14
ZA201003223B (en) 2011-04-28
CR11419A (es) 2010-08-27
WO2009061273A1 (en) 2009-05-14
MX2010005036A (es) 2010-05-27
CO6270343A2 (es) 2011-04-20
DOP2010000138A (es) 2010-06-15

Similar Documents

Publication Publication Date Title
DOP2010000138A (es) Formulaciones de polvo seco que comprenden derivados del acido ascorbico
CY1124928T1 (el) Αναστολεις πυραζολυλο κινοξαλινο κινασης
EP3600563C0 (en) PHARMACEUTICAL COMPOSITIONS COMPRISING VITAMIN D3 AND HYALURONIC ACID
CY1120605T1 (el) Παρασκευασμα ξηρης σκονης που περιλαμβανει εναν αναστολεα φωσφοδιεστερασης
FR2949062B1 (fr) Nouvelles formulations pharmaceutiques contre le mesusage des medicaments
MX339408B (es) Composiciones farmaceuticas entericas resistentes al alcohol.
BRPI0809667A2 (pt) Composto, medicamento e composição farmacêutica que o contém e uso do composto
AR067309A1 (es) Formulaciones farmaceuticas que contienen derivados de acido lipoico
HUE043555T2 (hu) Tetrahidrokannabinol gyógyszer elõanyagai (prodrugjai), kompozíciók, amelyek tetrahidrokannabinol gyógyszer elõanyagait tartalmazzák, és eljárások, ezek alkalmazására
AR059358A1 (es) Formulaciones farmaceuticas
CY1110221T1 (el) Σταθερα φαρμακευτικα σκευασματα νατριουχου μοντελουκαστης
UY31314A1 (es) Amidas heterociclicas y sus métodos de uso-976
EP2474522A4 (en) AGOME ELITE AND PHARMACEUTICAL COMPOSITIONS THEREOF
CR10229A (es) Derivados de 1,2,4,5,-tetrahidro-3h-benzazepinas, su procedimiento de preparación y las composiciones farmacéuticas que las contienen
CR10505A (es) Aminopirazolopiridinas sustituidas y sus sales, sus preparaciones y composiciones farmaceuticas que las comprenden
DOP2009000165A (es) Derivados de oxindol sustituido, medicamentos que los comprenden y uso de los mismos
CR20140144A (es) Derivados de estra-1,3,5 (10), 16-tetraen-3-carboxamida, procedimientos para su preparación, preparados farmacéuticos que los contienen, así como su uso para la preparación de medicamentos
DOP2015000005A (es) Derivados de estra 1,3,5(10), 16 tetraeno 3 sustituidos, métodos para su preparación, preparaciones farmacéuticas que los contienen, así como su uso para la preparación de medicamentos
CR10454A (es) Composiciones farmaceuticas novedosas de baja dosis que comprenden nimesulida , preparacion y uso de las mismas
CL2014003148A1 (es) Composición farmacéutica acuosa que contiene un agente terapéutico biológico y guanidina o un derivado de la guanidina y una inyección que incluye la composición.
MX340983B (es) Composiciones farmaceuticas y nutraceuticas de acido abscisico.
TR201000733A2 (tr) Flutikazon, tiotropyum ve sodyum kromoglikat içeren farmasötik bileşimler.
IL313924A (en) Pharmaceutical dry powder inhalation formulation
TR200907917A2 (tr) Kuru toz inhaleri.
EA201200485A1 (ru) Перорально распадающаяся фармацевтическая лекарственная форма, содержащая арипипразол